Combination of thiol antioxidant Silibinin with Brostallicin is associated with increase in the anti-apoptotic protein Bcl-2 and decrease in caspase 3 activity

Cancer Letters

Volumn 238, Issue 1, 2006, Pages 146-152

  Pook, Sim Hwee ^a   Toh, Chee Keong ^b   Mahendran, Ratha ^a  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

Antioxidants; Apoptosis; Bcl 2 proteins; Caspases; Chemotherapy

Indexed keywords

ACETYLCYSTEINE; ANTIOXIDANT; BROSTALLICIN; CASPASE 3; PROTEIN BCL 2; SILIBININ; THIOL;

ANTIOXIDANT ACTIVITY; ARTICLE; CELL STRAIN HEPG2; CONTROLLED STUDY; CYTOTOXICITY; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL;

ACETYLCYSTEINE; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIOXIDANTS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CASPASE 3; CASPASES; CELL LINE, TUMOR; DOWN-REGULATION; DRUG ANTAGONISM; DRUG SCREENING ASSAYS, ANTITUMOR; ENZYME ACTIVATION; GUANIDINES; HUMANS; NASOPHARYNGEAL NEOPLASMS; PROTO-ONCOGENE PROTEINS C-BCL-2; PYRROLES; SIGNAL TRANSDUCTION; SILYMARIN; SULFHYDRYL COMPOUNDS; UP-REGULATION;

EID: 33745022639     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2005.07.002     Document Type: Article

References (18)

1. D'Incalci M. DNA-minor-groove alkylators, a new class of anticancer agents. Ann. Oncol. 5 (1994) 877-878
2. Sessa C., Pagani O., Zurlo M.G., de Jong J., Hofmann C., Lassus M., Marrari P., Benedetti M.S., and Cavalli F. Phase I study of the novel distamycin derivative tallimustine (FCE 24517). Ann. Oncol. 5 (1994) 901-907
3. Wolff I., Bench K., Beijnen J.H., Bruntsch U., Cavalli F., de Jong J., Groot Y., van Tellingen O., Wanders J., and Sessa C. Phase I clinical and phamacokinetic study of carzelesin (U-80244) given daily for five consecutive days. Clin. Cancer Res. 2 (1996) 1717-1723
4. Punt C.J., Humblet Y., Roca E., Dirix L.Y., Wainstein R., Polli A., and Corradino I. Tallimustine in advanced previously untreated colorectal cancer- a phase II study. Br. J. Cancer 73 (1996) 803-804
5. Lockhart A.C., Howard M., Hande K.R., Roth B.J., Berlin J.D., Vreeland F., Campbell A., Fontana E., Fiorentini F., Fowst C., Paty V.A., Lankford O., and Rothenberg M.L. A Phase I dose-escalation and pharmacokinetic study of Brostallicin (PNU-166196A), a novel DNA minor groove binder, in adult patients with advanced solid tumors. Clin. Cancer Res. 10 (2004) 468-475
6. Geroni C., Marchini S., Cozzi P., Galliera E., Ragg E., Colombo T., Battaglia R., Howard M., D'Incalci M., and Brogginin M. Brostallicin, a novel anticancer agent whose activity is enhanced upon binding to glutathione. Cancer Res. 62 (2002) 2232-2236
7. Colvin O.M., Friedman H.S., Gamcsik M.P., Fenselau C., and Hilton J. Role of gluathione in cellular resistance to alkylating agents. Adv. Enzyme Regul. 33 (1993) 19-26
8. Moller P., and Loft S. Interventions with antioxidants and nutrients in relation to oxidative DNA damage and repair. Mutat. Res. 551 (2004) 79-89
9. Sun Y., and Oberley L.W. Redox regulation of transcriptional activators. Free Radic. Biol. Med. 21 (1996) 335-348
10. Havre P., O'Reilly S., McCormick J.J., and Brash D.E. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants, N-acetyl cysteine and penicllamine. Cancer Res. 62 (2002) 1443-1449
11. Hildeman D.A., Mitchell T., Aronow B., Wojciechowski S., Kappler J., and Marrack P. Control of Bcl-2 expression by reactive oxygen species. Proc. Natl. Acad. Sci. USA 100 (2003) 15035-15040
12. De Flora S., Izzotti A., D'Agostinin F., and Balansky R.M. Mechanisms of N-acetylcysteine in the prevention of DNA damage and cancer, with special reference to smoking-related end-points. Carcinogenesis 22 (2001) 999-1013
13. Zhao J., and Agarwal R. Tissue distribution of silibinin, the major active constituent of silymarin, in mice and its association with enhancement of phase II enzymes: implications in cancer chemoprevention. Carcinogenesis 20 (1999) 2101-2108
14. Bang J.H., Han E.S., Lim I., and Lee C.S. Differential response of MG132 cytotoxicity against small cell lung cancer cells to changes in cellular GSH contents. Biochem. Pharmacol. 68 (2004) 659-666
15. 2-M arrest, and apoptosis. Clin. Cancer Res. 8 (2002) 3512-3519
16. Wen J., You K.R., Lee S.Y., Song C.H., and Kim D.G. Oxidative stress-mediated apoptosis- the anticancer effect of the sesquiterpene lactone parthenolide. J. Biol. Chem. 277 (2002) 38954-38964
17. Yang C.C., Lin H.P., Chen C.S., Yang Y.T., Tseng P.H., Rangnekar V.M., and Chen C.S. Bcl-xL mediates a survival mechanism independent of the phosphoinositide 3-kinase/Akt pathway in prostate cancer cells. J. Biol. Chem. 278 (2003) 25872-25878
18. Luo D., Cheng S.C., Xie H., and Xie Y. Chemosensitivity of human hepatocellular carcinoma cell line QGY-7703 is related to bcl-2 protein levels. Tumour Biol. 20 (1999) 331-340